Early Phase 1 Myeloma Trial, Recruiting (NCT04211259)

Early Phase 1 Myeloma Trial, Recruiting NCT04211259 Sponsor: Rutgers, The State University of New Jersey Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT04211259 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are able to give their informed consent to take part in the trial
People who have a confirmed diagnosis of multiple myeloma
People who are able to swallow and keep down oral (by mouth) medication
People from all ethnic backgrounds are welcome to apply

Who may not be able to join:

People who do not speak English
People who are currently undergoing a specific type of stem cell transplant known as a haploidentical allogeneic transplant (confirm with trial site)
People who have known allergies, sensitivities, or intolerances to any of the medications or ingredients used in the study
People who have medical complications or conditions that, in the treating doctor's judgement, would prevent full participation in the study
People who have taken a therapeutic (higher) dose of aspirin — meaning more than 81 mg — within the 7 days before the study would begin

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Mansi R. Shah, MD, Rutgers Cancer Institute of New Jersey

Phone: 732-235-4439

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04211259

Sponsor: Rutgers, The State University of New Jersey

Phase: Early Phase 1

Status: Recruiting

Condition: Myeloma

Trial contact: 732-235-4439

More information: https://clinicaltrials.gov/study/NCT04211259

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are able to give their informed consent to take part in the trial
People who have a confirmed diagnosis of multiple myeloma
People who are able to swallow and keep down oral (by mouth) medication
People from all ethnic backgrounds are welcome to apply

Who may not be able to join:

People who do not speak English
People who are currently undergoing a specific type of stem cell transplant known as a haploidentical allogeneic transplant (confirm with trial site)
People who have known allergies, sensitivities, or intolerances to any of the medications or ingredients used in the study
People who have medical complications or conditions that, in the treating doctor's judgement, would prevent full participation in the study
People who have taken a therapeutic (higher) dose of aspirin — meaning more than 81 mg — within the 7 days before the study would begin

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Early Phase 1

Sponsor

Rutgers, The State University of New Jersey

Registry

ClinicalTrials.gov

Start date

18 April 2022

Est. completion

31 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in mean pain level for each group following therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov